Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...
CNBC

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a long ...
Time

Vertex Pharmaceuticals

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.
Business Wire

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
The Motley Fool

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.
CSO Online

Google Vertex AI security permissions could amplify insider threats

A new way to escalate privileges inside Google’s Vertex AI highlights a broader problem: Enterprises have a level of trust in ...
Seeking Alpha

Vertex Pharmaceuticals: Strategically Positioning For Future Success

Vertex Pharmaceuticals showed strong Q2 2023 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and U.S. growth. Management outlined growth initiatives in various ...